|
|
Дата |
|---|
| 22:47 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
3.75
|
3.96
|
3.20
|
3.00
|
4.10
|
3.75
|
|
|
264 859.81
|
485.00
|
|
3.09
|
3.21
|
3.31
|
3.13
|
3.36
|
3.20
|
|
|
75 336.67
|
177.00
|
|
3.00
|
4.18
|
3.50
|
3.3383
|
3.5787
|
3.47
|
|
|
13 855.65
|
88.00
|
|
1.45
|
4.18
|
3.83
|
3.44
|
3.83
|
3.45
|
|
|
38 650.93
|
120.00
|
|
3.71
|
4.18
|
3.81
|
3.7101
|
3.85
|
3.72
|
|
|
14 994.62
|
139.00
|
|
1.51
|
4.15
|
4.12
|
3.60
|
4.12
|
3.81
|
|
|
84 889.02
|
507.00
|
|
3.85
|
5.68
|
4.12
|
3.89
|
4.30
|
3.97
|
|
|
60 138.70
|
184.00
|
|
3.85
|
5.68
|
4.04
|
4.04
|
4.26
|
4.105
|
|
|
5 794.50
|
54.00
|
|
3.85
|
5.68
|
4.00
|
4.00
|
4.165
|
4.165
|
|
|
64 779.05
|
202.00
|
|
3.85
|
5.68
|
4.245
|
4.01
|
4.245
|
4.10
|
|
|
18 646.45
|
68.00
|
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells.
The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Показать все Скрыть